Safety Profile of Nulojix in Home Infusion Settings

• Status: Completed
• Trial end date: 2015-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The study is a retrospective cohort study that utilizes medical records from the BiologicTx. Data accrual starts upon initial home infusion nurse visit until the most recent home infusion nurse visit. Infusion related adverse events are quantified as number of patients with adverse event over the total number of patients and number of event over total number of home infusion visits.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Collaborator: BiologicTx, LLC
• Treatments: Abatacept

Criteria

Inclusion Criteria:

• All adult kidney-only transplant recipients currently receiving NULOJIX in BiologicTx home infusion service settings